"The Science Behind Logistics" Webinar, Hosted by Cryoport

IRVINE, Calif., Sept. 30, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company, announced today that Dr. Mark Sawicki, Chief Commercial Officer, is scheduled to present a webinar titled "The Science Behind Logistics" discussing how new therapeutic products require new technologies, capabilities, resources and a thorough understanding of how temperature impacts preclinical and clinical studies and commercialization of regenerative medicines, as follows:

In this webinar, Dr. Mark Sawicki, Chief Commercial Officer of Cryoport, will discuss results from sponsored research on the impact of packaging choices and temperature ranges on the viability of cells, biomarkers and critical reagents for pharmacokinetic/pharmacodynamics (PK/PD), immunogenicity and clinical studies. An overview of the research will be provided describing the impact on assay performance resulting from shipping under dry ice and dry vapor liquid nitrogen (LN2) cryogenic shipping conditions, especially at longer holding times associated with global supply chains. In addition, Dr. Sawicki will discuss the results of a separate study of cell viability and resultant GP19 production, a target of genetic alterations found in cancers. Real-world risk mitigation strategies will be presented for packaging, logistics, systems integration, condition monitoring and technology — elements that can impact clinical trial results, product integrity and efficacy as well as biomarker viability in the just-in-time logistics environment for clinical studies and the commercialization of regenerative medicines.

"Cryoport has a vested interest in providing the most accurate scientific data to support logistics strategies underpinning clinical research data generation to our clients. To that end, we have scheduled a webinar available to the scientific community to discuss the outcomes of research conducted in conjunction with our partners, Heat Biologics and Kansas City Analytical Services, looking at the impact of packaging and temperature on the viability of clinical materials. We believe this research provides valuable insight to the pharmaceutical industry that will impact logistics decisions and improve clinical data generation," said Dr. Mark Sawicki, Chief Commercial Officer of Cryoport.

To register for this webinar, please visit: www.cryoportwebinar.com

About Cryoport, Inc.

Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproductive medicine. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

• simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
• delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
• providing vital information that provides peace of mind throughout the life of each logistics process

For more information, visit www.cryoport.com. To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Logo - http://photos.prnewswire.com/prnh/20160524/371732LOGO

SOURCE Cryoport, Inc.